Gilead Sciences announced a definitive agreement to acquire an oral IL-23 receptor inhibitor program, including HCXT-2001, from privately held PepStar Therapeutics for $1.275 billion in upfront cash consideration, payable at closing and subject to customary adjustments.
HCXT-2001 is an investigational oral macrocyclic peptide inhibitor of IL-23R with an extended half-life, currently undergoing Phase I clinical testing; its safety and efficacy have not been established.
Gilead intends to investigate the compound as monotherapy and potentially in combination with emvistegrast, its oral α4β7 integrin inhibitor, which recently produced positive Phase II ulcerative colitis results.
The transaction provides worldwide rights to the acquired program and is expected to close in Q4 2026, subject to customary conditions. Gilead Investors
Primary sources: Gilead acquisition announcement — October 22 · Gilead SWIFT Phase II results — October 19
Why it matters strategically
The most significant feature is the transaction structure.
Gilead is not committing a relatively modest upfront payment followed by large contingent development milestones.
Instead, it is agreeing to pay $1.275 billion upfront for an early-stage program.
That transfers substantial development risk to the acquirer.
The distinction matters because Phase I success does not establish clinical efficacy in inflammatory bowel disease.
IL-23 is a clinically validated therapeutic pathway, but validation of a biological target does not automatically establish the value of a particular molecule.
HCXT-2001 must demonstrate that its oral delivery, pharmacokinetics, efficacy, safety, and treatment durability justify its positioning against existing therapies.
